{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000055","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.047694+00:00","generated_at":"2026-05-21T00:25:33.241922+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"AEON Biopharma presents corporate update at Aegis Capital Conference, focusing on PrabotulinumtoxinA","bullets":["Presentation highlights PrabotulinumtoxinA as a therapeutic botulinum toxin product candidate.","Corporate presentation made available on AEON's investor relations website on May 20, 2025.","No specific clinical data, financial results, or material changes disclosed in the furnished slides."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000055","json":"https://secwatch.observer/filing/0001837607-25-000055.json","markdown":"https://secwatch.observer/filing/0001837607-25-000055.md","text":"https://secwatch.observer/filing/0001837607-25-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000055/0001837607-25-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000055/aeon-20250520x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T00:25:33.241922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}